Zura Bio

1. Third indication undisclosed Ph2 startby year-end 2026Third indication undisclosed Ph2 start, by year-end 2026, routine
2. Tibulizumab TibuSHIELD topline4Q 2026Tibulizumab TibuSHIELD topline, 4Q 2026, thesis-defining
3. Tibulizumab TibuSURE topline1H 2027Tibulizumab TibuSURE topline, 1H 2027, major

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.